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Sex hormone–binding globulin (SHBG) determines the equi-
librium between free and protein-bound androgens and estro-
gens in the blood and regulates their access to target tissues.
Using crystallographic approaches and radiolabeled competi-
tive binding-capacity assays, we report here how two nonsteroi-
dal compounds bind to human SHBG, and how they influence
androgen activity in cell culture. We found that one of these
compounds, ()3,4-divanillyltetrahydrofuran (DVT), present
in stinging nettle root extracts and used as a nutraceutical, binds
SHBG with relatively low affinity. By contrast, a synthetic com-
pound, 3-(1H-imidazol-1-ylmethyl)-2phenyl-1H-indole (IPI),
bound SHBGwith an affinity similar to that of testosterone and
estradiol. Crystal structures of SHBG in complex with DVT or
IPI at 1.71–1.80 Å resolutions revealed their unique orienta-
tions in the SHBG ligand-binding pocket and suggested oppor-
tunities for the design of other nonsteroidal ligands of SHBG.As
observed for estradiol but not testosterone, IPI binding to SHBG
was reduced by20-fold in the presence of zinc, whereas DVT
binding was almost completely lost. Estradiol-dependent fibu-
lin-2 interactions with SHBG similarly occurred for IPI-bound
SHBG, but not with DVT-bound SHBG. Both DVT and IPI
increased the activity of testosterone in a cell culture androgen
reporter system by competitively displacing testosterone from
SHBG. These findings indicate how nonsteroidal ligands of
SHBG maybe designed to modulate the bioavailability of sex
steroids.
Steroid hormone bioavailability is delineated by the “free
hormonehypothesis” and its underlying tenet that steroids only
enter cells when they are not bound by plasma proteins (1). Sex
hormone–binding globulin (SHBG)2 is produced by hepato-
cytes and it binds biologically active androgens and estrogens,
thereby regulating their plasma levels and bioavailability (2).
Human SHBG is a homodimer, with each monomer compris-
ing two laminin G (LG) domains (3). The N-terminal LG
domain contains a steroid-binding site and the dimerization
interface (3, 4). The dimerization of SHBG depends on the
occupancy of a calcium-binding site within the N-terminal LG
domain and dimerization is stabilized by the binding of steroid
ligands (5). The carboxyl-terminal LG domain plays no role in
steroid binding or dimerization but contains two N-linked gly-
cosylation sites, the utilization of whichmay prolong its plasma
half-life (6, 7).
The active androgen, 5-dihydrotestosterone (DHT), has
the highest affinity 1 nM Kd for SHBG followed by testoster-
one and estradiol, which bind with 5 and 20 times lower
affinities, respectively, when compared with DHT (8). Andro-
gens and estrogens are positioned in opposite orientations
within the same hydrophobic pocket in crystal structures of the
N-terminal LG domain of SHBG such that the steroid ring A of
androgens is buriedwithin the protein near Ser-42, whereas the
ring D of estrogens resides in this position, and this steroid
class–dependent difference in their orientation causes minor
structural variation in the protein (9). Notably, a flexible loop
region formed by residues 130–135 appears to form a lid over
an entrance to the SHBG steroid-binding pocket. This loop
region usually appears disordered in crystal structures when
androgens are present in the binding site but is more ordered
when estradiol is bound so that key residues within it interact
with this steroid (9, 10). Occupancy of a zinc-binding site in this
region of human SHBG also alters the positioning of this loop
region and the binding affinity of estrogens (10–12).
Evidence that this flexible loop region serves as the main
portal for sex steroids is largely circumstantial. However, an
mAbbinds an epitope in this region, andpresumably constrains
the mobility of the loop, and this appears to prevent the move-
ment of DHT into and out of the steroid-binding site, whereas
the binding of estradiol is onlymarginally affected (13). This led
to the suggestion that estradiol has an alternative route of entry
into or exit from the steroid-binding site when compared with
This workwas supported by the Canadian Institutes of Health Research Grant
MOP 15261 (to G. L. H.) and the Canada Research Chair in Reproductive
Health Tier 1 (to G. L. H.). The authors declare that they have no conflicts of
interest with the contents of this article.
This article contains Fig. S1.
The atomic coordinates and structure factors (codes 6PYF, 6PYB, and 6PYA) have
been deposited in the Protein Data Bank (http://wwpdb.org/).
1 To whom correspondence should be addressed. E-mail: geoffrey.
hammond@ubc.ca.
2 The abbreviations used are: SHBG, sex hormone binding globulin; DHT,
5-dihydrotestosterone; DVT, ()3,4-divanillyltetrahydrofuran; IPI, 3-(1H-
imidazol-1-ylmethyl)-2phenyl-1H-indole; LG, laminin G; RMSD, root mean
square deviation; RBA, relative binding affinity; DCC, dextran-coated
charcoal.
croARTICLE
1202 J. Biol. Chem. (2020) 295(5) 1202–1211
© 2020 Round et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
 at U
niversity of H
elsinki on M
arch 1, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
DHT (13). If the steroid-binding pocket of SHBG has multiple
entrances, it is possible that other lipophilic ligands of SHBG
(14) access it differently and reside within it in unique
orientations.
Numerous nonsteroidal ligands of SHBG have been identi-
fied, including several endocrine disrupting compounds (14,
15). Among these, ()3,4-divanillyltetrahydrofuran (DVT) is a
natural compound present in stinging nettle root extracts used
for the treatment of benign prostatic hypertrophy (Fig. 1) (16,
17) and is widely used as a nutraceutical with anabolic proper-
ties (18).We therefore set out to determine themolecular inter-
actions between SHBGandDVT, aswell as a novel nonsteroidal
compound, 3-(1H-imidazol-1-ylmethyl)-2phenyl-1H-indole (IPI)
provided by Pfizer (PF-0102478) as a potential SHBG ligand (Fig.
1), and we have studied their ability to displace androgens from
SHBG and to enhance their bioavailability.
Results
Crystal structure of SHBG E176K in complex with estradiol
The N-terminal LG domain of human SHBG E176K crystal-
lizes within 24 h into large 3-dimensional diamond-shaped
crystals in space group P4322 that provide reliable data collec-
tion. The crystal structure of estradiol-bound SHBGE176Kwas
determined at 1.73Å and solved bymolecular replacementwith
the published N-terminal LG domain SHBG structure in com-
plex with estradiol (9). Data collection parameters and refine-
ment statistics are presented in Table 1.When these structures
are superimposed, the steroid-binding pocket, the flexible loop
region that covers it, and the position and orientation of estra-
diol do not differ from each other (Fig. 2A). Structural align-
ment of  carbon atoms between estradiol-bound E176K and
previously published estradiol-bound WT SHBG structures
resulted in aRMSDof 1.25Å. Residues involved in steroid bind-
ing are positioned as expected (Fig. 2B). Although the orienta-
tion of Trp-84 differs in position, its electron density in SHBG
E176K is poorly defined, indicating that there may be a second-
ary conformation for this residue. In addition, the side chain of
Lys-173 is displaced and a suspected water molecule is orga-
nized by hydrogen bonding between Lys-173 and Lys-176,
when compared with Glu-176 (Fig. 2C), and this change is
located near residues (Leu-171–Lys-173) that are displaced
when estradiol is bound (10).
Crystal structure of SHBG E176K in complex with DVT
The crystal structure of SHBG E176K in complex with DVT
was determined at 1.80 Å and solved bymolecular replacement
with the estradiol-bound SHBG E176K structure. This shows
that DVT is bound at same site as sex steroids but occupies
more of the hydrophobic pocket, whilemaintaining key residue
interactions (Fig. 3A). No major changes to the globular struc-
ture were observed when compared with other SHBG crystal
structures with several steroid ligands (Fig. 3A) (3, 9, 10). The
binding pocket was occupied by DVT in an orientation where
vanillyl group A and the THF ring sit in the same position as a
steroid, but the second vanillyl group B occupies a volume that
is normally emptywhen a steroid is bound (Fig. 3A). This crystal
structure implies that Ser-42 contributes significantly to the
binding of DVT, as observed for all SHBG ligands (14), but this
appears to be mediated through a water molecule that bridges
Ser-42 and the oxygen of the THF ring (Fig. 3B). The other key
interaction is a hydrogen bond between Asp-65 and the
hydroxyl group of vanillyl group A that appears to also hold the
ligand in place. A less significant contribution to binding is
implied for Arg-135, which borders the flexible lidlike loop that
is disordered (residues Leu-131–Ser-133) when DVT is bound
(Fig. 2A). Although Arg-135 reaches into the binding pocket, it
is not clear if it hydrogen bonds directly with DVT; instead, it
may stabilizes the contact with Asp-65 through an ionic inter-
action (Fig. 3B). The disordering of the loop is caused by DVT
displacing Leu-131 and an outward movement and rearrange-
ment of the loop that allows Arg-135 to stabilize DVT binding,
and this contrasts with the corresponding role of Lys-134 in
estradiol-bound structures (Fig. 3A). The positioning of Trp-
84, a surface residue near the flexible loop region of SHBG, in
the DVT-bound structure mirrors that in the estradiol-bound
SHBG structure (9).
Crystal structure of SHBG E176K in complex with IPI
The crystal structure of E176K SHBG in complex with IPI
was determined at 1.71 Å and solved bymolecular replacement
with the SHBG E176K estradiol-bound structure (Fig. 4). No
major changes to the globular structure of the protein were
noted, whereas structural variation occurred throughout the
binding pocket. The binding of IPI was determined by three
major interactions involving Ser-42, Phe-67, and Asp-65 (Fig.
3B). Serine 42 interacts with the nitrogen of the imidazole por-
tion of IPI through a hydrogen bond of 2.7 Å. Residue Phe-67
- stacks with IPI through its phenyl group at a distance of 4
Å. Interestingly, this interaction forces Phe-67 into an alternate
conformation as compared with when DVT or steroids are
bound (Fig. 4A). This conformation of Phe-67 rearranges the
hydrophobic binding pocket sufficiently to allow the perpen-
dicular positioning of IPI relative to DHT (Fig. 4A), which
leaves a large portion of the binding pocket empty in the IPI
Figure 1. Chemical structures of nonsteroidal ligands of SHBG. A, chemi-
cal structure of DVT, a plant-derived lignan. B, chemical structure of IPI, a
synthetic compound provided by Pfizer as a potential SHBG ligand.
Nonsteroidal ligands of SHBG
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Figure 2. Crystal structure of estradiol (orange) bound to the LG4 domain of E176K SHBG (yellow) modeled at 1.73 Å resolution.Hydrogen bonds are
indicated as dotted lines. Structure of WT SHBG-bound estradiol (PDB: 1LHU) (cyan, with estradiol highlighted blue) is overlaid for comparison. A, overlay of
E176K SHBG andWT SHBGwith estradiol bound, highlighting the similarity of the two structures and steroid positioning. One cycle alignment RMSD 1.25 Å
across all C atoms. All key residue side chains are in the same position for both structures. B, estradiol positioned in the binding pocket of E176K SHBG with
residues involved in the binding interaction shown. 2Fo Fcmap is shown around the ligand at 1.5 , carved at 3.0 Å. C, proposed alternative entrance to the
binding pocket is shown, with the E176K substitution and resulting hydrogen bond interaction with Lys-173 through a water molecule (red) shown.
Table 1
Data collection and refinement statistics
Statistics for the highest-resolution shell are shown in parentheses. One crystal was used for each dataset.
E2-bound E176K SHBG DVT-bound E176K SHBG IPI-bound E176K SHBG
Data Collection
Space group P 43 2 2 P 43 2 2 P 43 2 2
Cell dimensions
a, b, c (Å) 51.87, 51.87, 149.6 51.95, 51.95, 148.4 52.24, 52.24, 147.9
Total reflections 44,460 (4330) 39,386 (3802) 46,065 (4470)
Unique reflections 22,230 (2165) 19,693 (1901) 23,048 (2235)
Resolution range 42.6–1.73 (1.79–1.73) 29.5–1.80 (1.86–1.80) 25.7–1.71 (1.77–1.71)
Rmerge (%) 1.3 (18.0) 1.2 (21.0) 1.3 (13.0)
CC1/2 1 (0.929) 1 (0.910) 1 (0.959)
CC* 1 (0.981) 1 (0.976) 1 (0.989)
I/I 23.0 (4.2) 23.0 (3.1) 24.0 (4.4)
Completeness (%) 99.6 (100) 99.9 (100) 99.7 (100)
Refinement
Resolution 42.6–1.73 (1.79–1.73) 29.5–1.80 (1.86–1.80) 25.7–1.71 (1.77–1.71)
Rwork/Rfree (%) 18.4/22.1 20.3/23.1 18.5/21.6
Number of atoms
Protein 1395 1356 1412
Ligands 21 26 22
Water 186 110 121
Average B-factors
Protein 28.2 41.2 32.0
Ligands 19.5 45.8 27.4
Water 34.8 42.8 37.4
RMSD bond lengths (Å) 0.008 0.003 0.006
RMSD bond angles (°) 1.05 0.75 0.84
Ramachandran statistics
Favored regions (%) 95.9 95.8 97.1
Allowed regions (%) 4.1 4.2 2.9
Outliers (%) 0 0 0
Rotamer outliers (%) 0 0.7 1.3
Clash score 1.07 1.47 2.11
MolProbity score 1.11 (99th percentile of
similar resolution
structures)
1.20 (99th percentile of
similar resolution
structures)
1.14 (99th percentile of
similar resolution
structures)
Nonsteroidal ligands of SHBG
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structure, and this space is filled by water molecules (Fig. 4B).
Although Asp-65 is 6.9 Å away from IPI, two of these water
molecules imply binding through a water molecule bridge end-
ing at the nitrogen of the IPI indole group (Fig. 4B). The coor-
dination of these water molecules appears to be supported by
Arg-135, Asn-82, and Ser-128. Other residues that are impor-
tant in accommodating steroids are integral to the hydrophobic
pocket, and include Met-107 andMet-139 (3). In the IPI struc-
ture, Met-107 is modeled with multiple conformations appear-
ing to increase the hydrophobic area to accommodate the
Figure 3. Crystal structure of DVT (green) bound to the LG4 domain of
E176KSHBG(blue)modeledat1.80Åresolution.Anoverlayof thedifferences
between the crystal structure of E176K estradiol (yellow, estradiol is orange) and
the DVT-bound E176K SHBG highlights the key differences around the binding
pocket. One cycle alignment RMSD 1.02 Å across all C atoms. Water mole-
cules involved in the binding are shown as red spheres and hydrogen bonds are
indicated as dotted lines. A, DVT-SHBG (blue) is aligned with estradiol-SHBG (yel-
low) with thedifferences in the flexible loop region (disordered inDVT structure)
and key residues indicated. DVT and estradiol are compared in the binding site
highlighting the differences in the volume occupied by the nonsteroidal ligand.
B,DVTbindinginteractionsandtheresiduesformingthehydrophobicpocketare
shown.2FoFcelectrondensityat1.0andcarvedat3.0Å is shownaroundDVT
and thewatermolecules in the binding pocket.
Figure 4. Crystal structure of IPI (purple) bound to the LG4 domain of
E176K SHBG (blue) modeled at 1.71 Å resolution. An overlay of the differ-
ences between the crystal structure of E176K estradiol (yellow, estradiol is
orange) and the IPI-bound E176K SHBGhighlights the key differences around
the binding pocket. One cycle alignment RMSD 1.35 Å across all C atoms.
Watermolecules involved in the binding are shown as red spheres and hydro-
gen bonds are indicated as dotted lines. A, IPI-SHBG (blue) is aligned with
estradiol-SHBG (yellow) with the differences in the flexible loop region and
key positions of key residues indicated. IPI and estradiol are compared in the
binding site highlighting the differences in the volume occupied by the non-
steroidal ligand. B, IPI binding interactions and the residues forming the
hydrophobic pocket are shown. 2Fo  Fc electron density (1.5 ) is shown
around DVT and the water molecules in the binding pocket.
Nonsteroidal ligands of SHBG
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indole portion of IPI (Fig. 4B). Additionally, Leu-171 projects
1.0 Å further into the binding pocket when compared with
when estradiol is present (Fig. 4A). As in theDVT-bound struc-
ture, IPI binding shifts the loop region above the steroid-bind-
ing site outwards, as a result of Leu-131 being displaced by the
indole of IPI, and this also causes Lys-134 to move out of the
binding pocket and Arg-135 to orient toward the binding
pocket. In the IPI-bound structure, Trp-84 is positioned as it is
when DHT is bound (PDB: 1D2S).
Validation of SHBG interactions with the nonsteroidal ligands
DVT and IPI
Substitutions of specific residues within the N-terminal LG
domain of SHBG were made to validate crystal structure pre-
dictions of the interactions between SHBG and DVT or IPI
(Table 2). Surprisingly, a S42A substitution that reduces affinity
for DHT (19) resulted in an5-fold increased relative binding
affinity (RBA) for DVT when compared with that of DHT
(Table 2). By contrast, a D65A substitution abolished DVT
binding to SHBG, supporting the assumption that Asp-65
hydrogen bonds with the hydroxyl of vanillyl A. The binding of
DVT was also negatively impacted by the substitution of Arg-
135with leucine. TheN82A substitution resulted in an increase
in the RBA of DVT, likely caused by a more optimal conforma-
tion of the methoxy of vanillyl group A, as it appears that
Asn-82 does not contribute a significant hydrogen bond to this
interaction. Substitutions of residues within the hydrophobic
pocket, Met-107, Met-139, and Phe-67 by smaller amino acids,
resulted in modestly increased RBA for DVT (Table 2).
The most significant residues contributing to IPI binding
from the crystal structure appear to be Asp-65, Ser-42, and
Phe-67. AD65A substitution decreases the RBAof IPI (Table 2)
that is unlikely to be because of a structural change in the bind-
ing site, but it supports the possibility that Asp-65 contributes a
hydrogen bond through water molecules (Fig. 3A). The SHBG
S42Amutant showednodetectable competitive binding for IPI,
supporting the predicted hydrogen bond between IPI and Ser-
42. Study of the SHBGR135Lmutant indicates that this residue
does not contribute significantly to the binding of IPI, as was
also observed for theN82A substitution. However, substitution
of hydrophobic residues in the steroid-binding pocket caused
changes in the affinity of SHBG for IPI. The F67A substitution
greatly reduced the RBA of SHBG for IPI, which was expected
because of the predicted importance to binding of the -
stacking interaction occurring between the phenyl groups of
IPI and Phe-67. The SHBGM139V mutant did not change the
RBA for IPI, whereas the M107V mutant appears to have an
increased affinity for IPI. Given the multiple conformations of
Met-107 in the IPI-bound SHBG structure, it is reasonable to
assume that the substitution of this residue with a smaller
hydrophobic residue likely allows the orientation of IPI to be
adjusted allowing for other interactions to be optimized.
Influence of high Zn2 concentrations on the binding of DVT
and IPI to SHBG
The relative affinities of SHBG for DVT and IPI were 1.5 and
74% of that measured for testosterone, respectively (Fig. 5A).
These competition curves also demonstrate that the affinity for
DVT is considerably lower than that of estradiol (34.2%),
whereas IPI binds with a higher affinity than estradiol and
almost as well as testosterone (Fig. 4A). We also found that
()3,4-dibenzyltetrahydrofuran, a compound lacking the hy-
droxyl and methoxy groups of DVT, binds SHBG very poorly
with an IC50 value10 M.
Saturation of the SHBG zinc-binding site within the flexible
loop region that covers the steroid binding pocket was also
tested to determine how this might influence the relative bind-
ing affinities for DVT and IPI (Fig. 5B). This demonstrated that
the affinities of SHBG for DVT and IPI were both negatively
impacted in the presence of high Zn2 concentrations. Under
Table 2
IPI and DVT competitive binding analysis of CHO expressed SHBG
mutants of key binding interaction residues identified from the struc-
ture model
For WT SHBG and different SHBG mutants, IC50 values for IPI and DVT were
calculated from competitive displacement of [3H]DHT using unlabeled DHT as the
reference. Errors were established using the 95% confidence interval of the IC50
values produced from nine concentration point displacement curves. The RBA
values were calculated by expressing the DHT IC50 values of IPI or DVT as a per-
centage of the DHT IC50s for WT SHBG or given mutant, thereby allowing com-
parisons of mutants where DHT affinity was also changed relative to WT SHBG.
NCD, no competitive displacement.
SHBG
mutant
DHT
IC50 (nM)
IPI
IC50 (nM)
DVT
IC50 (nM)
IPI
(RBA%)
DVT
(RBA%)
Wildtype 4.7 0.7 55 7 2500 370 8.5 0.19
D65A 4.0 1.8 430 160 NCD 0.93 NCD
M107V 3.6 1.0 7.6 1.3 690 350 47 0.52
M139V 4.6 1.7 41 27 590 370 11 0.78
F67A 5.1 1.6 390 240 820 320 1.3 0.62
R135L 3.0 0.6 30 13 3100 1600 10 0.10
N82A 3.3 1.2 23 7 310 180 14 1.1
E176K 14 2 150 16 4200 790 9.3 0.33
S42A 42 9 NCD 4100 950 NCD 1.0
Figure 5. Competitive steroid binding assays. A, steroid binding assays
preformed on diluted human serum, using [3H] DHT as a tracer, and unla-
beled IPI, DVT, estradiol, and testosterone at increasing concentrations to
establish displacement curves. The relative binding affinity of IPI, DVT, and
estradiol compared with testosterone we found to be 74, 1.5, and 34%,
respectively. B, competitive steroid-binding assays assess IPI, DVT, estradiol,
and testosterone at increasing concentrations to establish displacement
curves with the addition of 1mM zinc chloride. The relative binding affinity of
IPI,DVT, andestradiol comparedwith testosterone in thepresenceof zincwas
found to be 3.7%, no binding, and 6.6%, respectively.
Nonsteroidal ligands of SHBG
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these conditions, the SHBG affinity for testosterone is
unchanged whereas its affinity for estradiol is markedly
reduced (Fig. 5, A versus B), as reported previously (11). In the
presence of high Zn2 concentrations, DVT showed no detect-
able binding at all, whereas the affinity of SHBG for IPI was
markedly reduced (by 20-fold) when compared with that of
testosterone (Fig. 5B), and this effect was greater than5-fold
reduction in the affinity for estradiol, relative to that of
testosterone.
Interaction between SHBG and fibulin-2 is influenced DVT and
IPI
The influence ofDVTand IPI on the ligand-dependent inter-
action between SHBG and fibulin-2 was assessed in a GST:
fibulin-2 pulldown assay followed by Western blotting. A neg-
ative control (Sepharose linked to GST alone) confirmed that
the presence of the carboxyl-terminal region of fibulin-2 is
required to pull down human SHBG from a diluted serum sam-
ple (Fig. 6A). As reported previously (20), the saturation of the
SHBG-binding site by estradiol under these conditions
increased the interaction between fibulin-2 and SHBG signifi-
cantly (p  0.007), when compared with that observed using
unliganded SHBG (Fig. 6B). Importantly, this interaction was
not influenced by the binding of DVT to SHBG, whereas IPI
enhanced the SHBG interaction with fibulin-2 significantly
(p 0.0403), and to a similar extent as that observed when the
SHBG-binding site was fully occupied by estradiol (Fig. 6B).
DVT and IPI enhance the bioavailability of testosterone
Using a cell line that stably expresses the androgen receptor
and a luciferase reporter gene under the control of an androgen
response element, we measured how the competitive displace-
ment of testosterone from SHBG in culture media by DVT or
IPI influenced androgen responses. The results indicate that
the addition of 10 nMSHBGalone to the culturemediumhas no
effect in the absence of testosterone, nor did the same concen-
tration of heat-inactivated SHBG (Fig. 7). In the absence of
SHBG, a robust 15-fold increase in luciferase response was
observed upon treatment with 10 nM testosterone, and the
presence of heat-inactivated SHBG had no effect on this. By
contrast, the presence of 10 nM SHBG almost completely sup-
pressed the activity of the same concentration of testosterone.
The addition of 1 M DVT alone did not cause an androgen
response, whereas the addition of 500 nM (p 0.0001) and 1M
DVT (p 0.0002) both cause significant increases in androgen
activity when incubated together with 10 nM SHBG and 10 nM
testosterone. The addition of 500 nM IPI alone also hadno effect
on androgen response and was muchmore effective in increas-
ing androgen responses in the presence of 10 nM SHBG and 10
nM testosterone at both the 100 nM (p 0.004) and 500 nM (p
0.0114) concentrations, as compared with DVT. This likely
reflects the much higher affinity of SHBG for IPI when com-
pared with DVT (Fig. 5A).
Discussion
The N-terminal laminin G domain of the natural SHBG
mutant E176K crystalizes efficiently and represents an ideal
structure for crystallization studies. Although it has an
increased affinity for estradiol (13), it binds DVT or IPI with
affinities similar to those of WT SHBG (Table 2). Our crystal
structure data suggest that the higher affinity of SHBG E176K
for estradiol may be because of an increase in the size of an
alternative entrance to the binding pocket (13), as illustrated
(Fig. 2). The increased affinity of SHBG E176K for estradiol is
explained by the outward displacement of Lys-173 at the rim of
Figure 6. Ligand-dependent interaction between SHBG and fibulin-2. A,
GST:fibulin-2 (1081–1157) was immobilized on GSH beads and incubated
overnightwith diluted serum containing 20 nMhuman SHBG, in the presence
and absenceof 100nMestradiol, DVT, or IPI. Thebeadswerewashed and then
boiled in SDS loading buffer for analysis by Western blotting. B, this graph
shows the relative amount of SHBG immunoreactivity (mean  S.D. in red
with individual data points as black squares) for each condition as measured
by densitometry of three pulldowns shown in the above Western blotting.
Significant differences determined using an unpaired t test from the stripped
control, to which no ligand was added, are as indicated; *, p  0.05; **, p 
0.005.
Figure7.CV1SHBG-dependentandrogenresponseassay luciferasedata
indicating that SHBG restricts the bioavailability of testosterone and
nonsteroidal ligands are capable of increasing the bioavailability in a
dose-dependent manner. DVT was found to slightly increase the bioavail-
ability of testosterone (T), whereas IPI was significantly more effective. Data
are from three experiments expressed as mean S.D. in red with individual
data points as black squares. An unpaired t test was applied to compare the
statistically significant difference between experimental samples to the T
SHBG baseline. *, p  0.05; **, p  0.005;***, p  0.0005. Heat treatment of
SHBG confirmed that no androgens remained bound to SHBG after stripping
and purification.
Nonsteroidal ligands of SHBG
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this possible entrance to the steroid-binding pocket. Impor-
tantly, because the affinities of IPI and DVT for SHBG E176K
versus WT SHBG are virtually identical, these nonsteroidal
ligands probably do not access the steroid-binding site in the
same manner as estrogens.
The crystal structures of SHBG-bound DVT or IPI provide
insight into how the steroid-binding pocket accommodates
ligands that do not resemble the typical cyclopentanophenan-
threne structure of steroids. The large volume occupied by
DVT in the steroid-binding site and the presence of a water
molecule bridging the ligand–Ser-42 hydrogen bond is unique
to the DVT-bound SHBG structure. Moreover, this water-
bridged hydrogen bond does not appear to be as important an
interaction for binding as it is for steroid ligands or IPI, as dem-
onstrated by the increased affinity of the SHBG S42A mutant
for DVT. Indeed, we predict that the increased affinity of SHBG
S42A for DVT is caused by the removal of the water molecule
bridging the hydrogen bond interaction, allowing forDVT to be
positioned deeper into the binding pocket, thereby optimizing
other interactions with the function groups of DVT.
The contrasting positioning of Arg-135 and Lys-134 in the
DVT-bound versus steroid-bound SHBG structures shows that
the flexible loop region over the steroid-binding pocket is
adaptable, and can fulfill its role of stabilizing ligand binding
through direct interactions with both the ligand and the sur-
rounding residues. The apparent interaction between Arg-135
andAsp-65 in theDVT-bound SHBG structuremay replace the
coordination of Asp-65 by Thr-60 seen when steroids are
bound (10). The role of Arg-135 also follows closely the stabi-
lizing role of Lys-134 when SHBG is bound by steroids (9). The
binding of DVT requires an interaction with Asp-65 that
anchors the molecule near the entrance to the binding pocket,
contrasting with steroids that only show a reduction in affinity
when Asp-65 is unable to hydrogen bond. The observations
made from the study of DVT show how SHBG binds small
nonsteroidal compounds with even modest affinity. Moreover,
the unique position of DVT within the SHBG ligand-binding
site provides a framework for modeling studies (14, 21–23) to
identify other molecules that bind SHBG with greater affinity.
The crystal structure of IPI bound to SHBG also demon-
strates a conformation of the binding pocket that has not been
described previously. This unique conformation allows for key
residues involved in binding steroids to maintain their role,
while changing the topography of the hydrophobic pocket. For
example, the alternate conformation of Phe-67 accommodates
the unique orientation of IPI relative to steroids (Fig. 4A). The
presence of four water molecules in the binding site of the IPI-
bound SHBG crystal structure is also novel for SHBG ligands.
The key hydrogen bond interaction between IPI and Asp-65 is
coordinated through two organized water molecules, incurring
an entropic cost of the binding. Similarly, the altered Phe-67
conformation may contribute negatively to the overall binding
energy of IPI. Interestingly, these energetic penalties are over-
come by the positioning of IPI in the binding pocket and the
strength of the ligand-protein interactions allowing IPI to be
boundwith high affinity.Modifications to the IPI structure that
maintain Asp-65 hydrogen bonding without the need of orga-
nized water molecules could result in a higher affinity for
SHBG.Moreover, the flexibility of the SHBG binding pocket to
accommodate IPI, like DVT, suggests that SHBG is capable of
binding a wider range of nonsteroidal molecules, in this novel
binding pocket orientation, with higher affinities than reported
to date.
The binding of DVT and IPI by SHBG is altered by the pres-
ence of zinc, as is the case for estradiol (11). When zinc is pres-
ent, Asp-65 is in an alternate conformation limiting its ability to
interact with ligands, and this causes a similar removal of the
hydrogen bonding partner, as expected in the SHBG D65A
mutant that has a reduced affinity for IPI and no measurable
DVT binding. The significance of the affinity changes for estro-
gens caused by zinc is unclear, but it may influence the role of
SHBG in specific anatomical locations where zinc concentra-
tions are very high, such as in the male reproductive tract (11).
This similarity in the way SHBG loses affinity for these non-
steroidal ligands and estrogens in the presence of high concen-
trations of zinc raises the question ofwhether theymodify other
activities of SHBG inways that are enhancedmost effectively by
estrogens, such as interactions with members of the fibulin
family of matrix-associated proteins (20).
Human SHBG interacts with the carboxyl-terminal domains
of the matrix associated proteins, fibulin-2 and fibulin-1D,
in a steroid-ligand–dependent manner (20). This interaction
occurs most efficiently when the steroid-binding site was occu-
pied by estradiol, and occupancy of the SHBG steroid-binding
site by estradiol appears to promote the extravascular seques-
tration of plasma SHBG in some tissues (20). We therefore
examined whether DVT or IPI interactions with SHBG might
alter its interactions with fibulin-2. Unlike estradiol, the bind-
ing of DVT to SHBG did not increase its interaction with fibu-
lin-2, whereas IPI promoted a similar interaction between
SHBG and fibulin-2 as that observed when its binding site is
occupied by estradiol. The fibulin-2 binding of SHBG that is
enhanced by estradiol has been attributed to a structural differ-
ence in SHBG when androgens and estrogens are bound, pri-
marily around the flexible loop region of its amino-terminal LG
domain (14, 20). The structure of IPI does not clarify this
because the loop region is organized in the IPI-bound SHBG
and differs in orientation as compared to when estradiol is
bound. Moreover, the position of Trp-84 varies between the
IPI-bound and estradiol-bound structures which both bind
fibulin. Although the exact interactions behind the binding of
SHBG to fibulin-2 have yet to be deciphered, the enhancement
of this interaction by IPI, in contrast with the lack of effect of
androgens orDVT, suggest that the binding of IPI to SHBGmay
promote its compartmentalization in specific tissues in the
body in a manner similar to observed for estradiol-bound
SHBG (20).
The primary roles of SHBG are to transport sex steroids in
plasma and extravascular compartments and to control the
amounts of sex steroids that can access target cells (2). Addi-
tionally, it represents a reservoir of sex steroids that is protected
from metabolic clearance. This reservoir also offers an oppor-
tunity to liberate endogenous steroids from their SHBG-bind-
ing site by displacement with a competitive ligand. To test this,
CV1 cells that express the androgen receptor and a luciferase
reporter under the control of an androgen response element
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were used to determine whether testosterone could be dis-
placed from SHBG by nonsteroidal ligands in vitro. Our results
show that both IPI and DVT are effective in this manner and
enhance androgen action in this reporter system.Moreover, the
luciferase responses are directly related to the relative affinities
of SHBG forDVT and IPI. These results are interesting because
DVT is reported to be the active component of natural health
products that are claimed to increase the bioavailability of tes-
tosterone (18). There is therefore reason to believe that high
affinity nonsteroidal ligands of SHBG like IPI may offer a much
more effective way to liberate steroids from SHBG in biological
fluids, thereby augmenting the activities of endogenous ste-
roids or exogenous steroids used for hormone replacement. In
this context, it is important to note that the affinity of SHBG for
IPI not only approaches that of testosterone but is several times
greater than that of estradiol. Thus, in addition to increasing
androgen action as shown in our in vitro experiments, com-
pounds such as IPI could be used to enhance both androgen and
estrogen action through their competitive displacement from
SHBG in vivo. The crystal structures we have obtained for
SHBG in complex with these nonsteroidal compounds, and the
ways they act to alter SHBG activities in different contexts, also
provide a framework for additional design of even more potent
ligands that could be used for these purposes.
Experimental procedures
SHBG ligands
Steroids, DHT, testosterone, and estradiol (Steraloids) and
[3H]DHT (specific activity 60 Ci/mmol, PerkinElemer Life Sci-
ences)were usedwithout further purification.DVTand aDVT-
related compound, 3,4-dibenzyltetrahydrofuran, were synthe-
sized in purities of98% (24). A preparation of IPI was kindly
provided by Pfizer and used for the purification of the human
SHBG N-terminal LG domain in Escherichia coli and obtained
commercially (Enamine) at 95% purity for crystallographic
determinations and biochemical analyses.
Human SHBG for crystallography
The N-terminal LG domain (residues 1–205 of the mature
polypeptide) of SHBG E176K was expressed as a GSH-S trans-
ferase (GST) fusion protein in a pGEXT2 expression vector (GE
Healthcare) in RossetaTM E. coli (MilliporeSigma). Cultures
were grown to 0.7 A600 before induction with 0.2 mM isopropyl
1-thio--D-galactopyranoside at 22 °C for 16 h. Cells were col-
lected and lysed by sonication in Tris-buffered saline (50 mM
Tris, 150 nM NaCl, pH 8.5)  2.5 mM CaCl2  5 M estradiol,
DVT or IPI. Cell lysates were spun at 30,000	 g for 30min and
then passed across a 10-ml bed of Pierce GSH Superflow Aga-
rose beads (Thermo Fisher Scientific) at room temperature.
The column was then washed with 10 volumes of the same
buffer before on-column cleavage with a column volume of 10
units of thrombin/milliliter overnight at room temperature.
After elution, fractions containing SHBG steroid-binding activ-
ity were pooled and concentrated for FPLC purification using
a Superdex 75 size exclusion chromatography column (GE
Healthcare). Size exclusion fractions containing SHBG were
pooled and mixed with PierceTM Glutathione Magnetic Aga-
rose Beads for 4 h at room temperature to remove any residual
GST before concentration in an Amicon Ultra 3000 MWC
centrifugal filter (MilliporeSigma) to 10mg/ml, and then buffer
exchanged to 50 mM HEPES, pH 7.5, containing 2.5 mM CaCl2
and 10 M estradiol, DVT, or IPI.
Crystallization and structure determination
Crystals of SHBG E176Kwere grown using the hanging drop
method in a reservoir solution of 20% PEG 3350, 0.2 M potas-
sium thiocyanate, and 5 M estradiol or 10 M DVT or IPI at
22 °C. Crystals of SHBG E176K in complex with estradiol were
grown using 1 l of protein solution mixed with 1 l of reser-
voir solution. Crystals appeared within 48 h and grew to maxi-
mum size after 5 days. In light of the ease of crystallization, the
reliability of diffraction data collection, and similarity between
the estradiol-bound SHBG E176K crystal structures and other
available crystals structures of SHBG, we used SHBGE176K for
further crystallization studies.
Crystals of SHBG in complex with DVT or IPI were grown in
the same way, with an additional seeding of a 1:10,000 dilution
of a crushed estradiol-bound SHBG E176K crystal to facilitate
crystallization and growth to a maximal size in 5 days. Crystals
were frozen in a cryo-solution of 30% ethanol, 20% PEG 3350,
0.2 M potassium thiocyanate, and 14 M estradiol or 10 M IPI
or DVT for data collection. Diffraction data for SHBG in com-
plex with estradiol were collected at the Stanford Synchrotron
Radiation Lightsource (SSRL, Stanford, CA) and processed
using HKL3000 (25). Diffraction data for DVT and IPI were
collected at the Advanced Photon Source beamline and pro-
cessed using XDS (26). All phases were determined by molecu-
lar replacement with Phaser (27) using a previously solved
SHBGcomplexed estradiol structure (PDB1LHU) as the search
model for SHBG E176K in complex with estradiol, which was
then used as the search model for both DVT- and IPI-bound
SHBG structures. Models were completed with iterative cycles
of manual model building in Coot (28) and refinement with
PHENIX (29). Prior to the addition of ligand structures to the
model, electron density was assessed to ensure ligand density
was present and complete (Fig. S1). RSRZ outliers occurred in
all structures in the amino and carboxyl termini, as well as the
flexible loop near the binding pocket; this is consistent with
previously published structures of SHBG. Structure files are
available from the RCSB database with accession codes 6PYF,
6PYB, and 6PYA, for estradiol-bound, DVT-bound, and IPI-
bound E176K SHBG structures, respectively.
Human SHBG andmutants with amino acid substitutions
Serum from transgenic mice containing high concentrations
of human SHBG (30) was treated twice at 37 °C for 30min with
dextran-coated charcoal (DCC) to remove steroids and then
diluted 10-fold in 20 mM Tris, pH 7.5, prior to FPLC Mono-
QTM column chromatography (GE Healthcare) to separate
SHBG fromalbumin. Fractions containing SHBG, as confirmed
by steroid-binding activity, were pooled and treated with DCC
twice at 37 °C for 30 min to remove steroids. The sample was
then concentrated, and buffer exchanged using a 10-kDa
molecularweight cut-off Amicon centrifugal filter into phenol
red free DMEM-F12 medium (Thermo Fisher Scientific) con-
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taining 10% charcoal stripped fetal bovine serum (FBS) for use
in androgen response assays (31).
To produce human SHBG mutants with specific amino acid
substitutions, an SHBG cDNA in PRC/CMVwas used to create
expression vectors for the desired mutant SHBG, as described
previously (13). Plasmids were transfected into CHO-S cells
using Lipofectamine 2000 (Invitrogen), and cells were grown
under 1mg/mlG418 selection inMEM containing antibiotics
(penicillin and streptomycin) and 10% FBS for 3 weeks to gen-
erate stable cell lines. Stable cell lines were grown to 80%
confluence before the media were changed to HyCloneTM
SFM4 CHO-utilityTM (Fisher Scientific) plus antibiotics and
100 nM DHT for 5 days before media containing SHBG were
harvested for analysis.
Steroid-binding assays
A steroid ligand saturation analysis was used to measure the
steroid-binding capacity of SHBG and its RBA for different
ligands (32). Briefly, CHO media or a human serum sample
containing 94 nM SHBG were treated with DCC to remove ste-
roids prior to equilibration with [3H]DHT in the presence or
absence of 100-fold molar excess DHT to determine nonspe-
cific binding. Unbound steroid was removed by exposure to
DCC for 10min at 0 °C followed by centrifugation, allowing for
the SHBG-bound [3H]DHT to be measured. The RBA values
were determined by using [3H]DHT as the labeled ligand and
increasing amounts of competitors in the presence or absence
of 1 mM ZnCl2 (11, 32).
Fibulin-2 pulldown assay
A GST:fibulin-2 fusion protein was produced in BL21 E. coli
using cDNA encoding carboxyl-terminal residues 1081–1157
of fibulin-2 in pGEX KGK (Amersham Bioscience), as de-
scribed previously (20). Briefly, bacterial cultureswere grown to
0.7 A600 before induction with 0.2 mM isopropyl 1-thio--D-
galactopyranoside at 22 °C for 16 h. Cells were collected and
lysed by sonication in Tris-buffered saline  0.02% Triton
X-100. Cell lysates were spun at 30,000	 g for 30min and then
processed by batch over 1ml of Pierce GSH Superflow Agarose
beads (Thermo Fisher Scientific) at 4 °C. The beads were then
washed with 10 volumes of the same buffer before use in pull-
down assays. A GST empty vector, pGEX KGK, was expressed
and purified following the same protocol as a negative control.
Transgenic mouse serum containing 20 nM human SHBG was
treated twice with DCC at 37 °C before 100 nM estradiol, DVT,
or IPI was added.Overnight incubationwith SHBGand 50l of
GST:fibulin-2 beads or GST beads was performed at 4 °C in
binding buffer (20 mM Tris-HCl, pH. 8.0, 0.02% Nonidet P-40).
Beads were sedimented and washed three times with ice-cold
binding buffer before being boiled in SDS-PAGE loading buffer
for 5 min for the detection of SHBG by Western blotting (20).
Androgen response assay
Monkey CV1 cells stably transfected with androgen receptor
and an androgen receptor response elementGaussia luciferase
construct (31) were kindly provided by Dr. William Rainey
(AnnArbor,MI). TheCV1 cells were seeded in 48-well plates at
40,000 cells/well and cultured in phenol red free DMEM-F12
supplemented with 10% charcoal-stripped (steroid free) FBS
and antibiotics. The following day the cells were treated with
10 nM SHBG and 10 nM testosterone in the absence or presence
of increasing amounts of DVT or IPI, and 10 nM heat-inacti-
vated (1 h at 60 °C) SHBG was used as a negative control. After
16 h, the culture medium was collected for luciferase analysis
on a Victor3V plate reader (PerkinElmer), as described (31).
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